Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Study of LY2140023 vs Atypical Antipsychotic Standard of Care in Schizophrenia
jRCT2080221371Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pomaglumetad methionil in schizophrenia (2 arms), sponsored by Eli Lilly and Company.
02
Drugs
pomaglumetad methionil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080221371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221371.